DealsAmpersand sells Nexcelom Bioscience for $260mAmpersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million.ByIris Dorbian25 June 2021•2 mins readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs